As with most medical progress, the rapid advancement in treatment modalities for various forms of cardiovascular disease has been made possible in part by a better understanding of disease pathology.
As with most medical progress, the rapid advancement in treatment modalities for various forms of cardiovascular disease has been made possible in part by a better understanding of disease pathology.
Despite the many advances in clinical care for the treatment of acute myocardial infarction (MI) and heart failure (HF), cardiogenic shock (CS) survival remains unchanged at 40%. For MI patients alone, the 30-day mortality rate is 40-50%, and it has remained at this level for the last two decades.